A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

Ganesh Raghu, Majd Mouded, Daniel C. Chambers, Fernando J. Martinez, Luca Richeldi, Lisa H. Lancaster, Mark J. Hamblin, Kevin F. Gibson, Ivan O. Rosas, Antje Prasse, Guolin Zhao, Michael Serenko, Natasha Novikov, Amy Mccurley, Prashant Bansal, Christopher Stebbins, Million Arefayene, Stella Ibebunjo, Shelia M. Violette, Diana GallagherJürgen Behr

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Lingua originaleEnglish
pagine (da-a)1128-1139
Numero di pagine12
RivistaAmerican Journal of Respiratory and Critical Care Medicine
Volume206
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • Antibodies, Monoclonal
  • Double-Blind Method
  • Humans
  • Idiopathic Pulmonary Fibrosis
  • Immunoglobulin G
  • Treatment Outcome
  • anti-αvβ6 IgG1 monoclonal antibody
  • idiopathic pulmonary fibrosis
  • randomized clinical trial
  • safety
  • treatment efficacy

Cita questo